# Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula

> **NCT05116072** · PHASE1,PHASE2 · RECRUITING · sponsor: **University Hospital, Lille** · enrollment: 36 (estimated)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Adenocarcinoma of the Duodenum
- Ampullary Adenocarcinoma

## Interventions

- **PROCEDURE:** total pancreatectomy
- **BIOLOGICAL:** intraportal islet autotransplantation

## Key facts

- **NCT ID:** NCT05116072
- **Lead sponsor:** University Hospital, Lille
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-20
- **Primary completion:** 2028-02-20
- **Final completion:** 2030-02-20
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116072, "Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05116072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*